Insilico Medicine

Insilico reports 40+ therapeutic programs, 31 preclinical candidates since 2021, 13 IND approvals, and a generative-AI-discovered drug advancing into Phase III.

Insilico reports 40+ therapeutic programs, 31 preclinical candidates since 2021, 13 IND approvals, and a generative-AI-discovered drug advancing into Phase III.

Insilico initiated a Phase III trial for Rentosertib, an AI-identified-target and AI-designed molecule, after positive Phase IIa results; by September 2026 the first Phase III patient had been dosed, demonstrating clinical translation of its generative-AI discovery platform.

Insilico develops an end-to-end Pharma.AI platform spanning target discovery, chemistry, clinical development, specialist models and agentic research tools.

Insilico develops an end-to-end Pharma.AI platform spanning target discovery, chemistry, clinical development, specialist models and agentic research tools.

Insilico Medicine has built an integrated generative-AI drug-discovery stack spanning target identification, chemistry generation and clinical development, with its AI-discovered and AI-designed Rentosertib advancing into Phase III after positive Phase IIa results.

Insilico combines AI research, clinical-stage biotech execution and major pharmaceutical partnerships including Takeda and others.

Insilico combines AI research, clinical-stage biotech execution and major pharmaceutical partnerships including Takeda and others.

Insilico reported approximately $106M revenue in H1 2026, up 287% year over year, adjusted net profit above $51M, and approximately $7.3B of announced 2026 transaction value across collaborations with global pharmaceutical partners.

Insilico describes ReLEHF for Chemistry42: experts rate generated structures and supply comments about toxicity or novelty, with feedback used to improve relevant ADME predictors and generation modules; predictive systems also reward or penalize generated molecules against target properties.

AI and generative-model skills transfer broadly, but medicinal chemistry, biology and clinical development remain important domain constraints.

AI and generative-model skills transfer broadly, but medicinal chemistry, biology and clinical development remain important domain constraints.